睿知中国疾病研究地图
候选清单0

即将招募食管鳞状细胞癌I期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Becotatug Vedotin Plus Cisplatin and Radiotherapy in LA-ESCC

ClinicalTrials.gov 上登记的一项食管鳞状细胞癌开放试验,由河北医科大学第四医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方河北医科大学第四医院Fourth Hospital of Hebei Medical University石家庄医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07697040,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 8

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(8 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. Histologically confirmed esophageal squamous cell carcinoma staged as cT2-T4a, N0-N+, M0-M1 (M1 limited to supraclavicular lymph node metastasis only).

    入选标准第 3 条

  3. Congestive heart failure (defined as New York Heart Association [NYHA] Class III or IV), myocardial infarction, unstable angina, coronary angioplasty, stent implantation, coronary artery bypass grafting, cerebrovascular accident (CVA), or hypertensive crisis within 6 months prior to enrollment.

    排除标准第 10 条

  4. Female subjects must not be pregnant or breastfeeding. Female or male subjects of childbearing potential must agree to practice effective contraceptive measures throughout the study period and for 6 months after completion of study treatment.

    入选标准第 15 条

  5. ECOG score of 0 or 1.

    入选标准第 6 条

  6. Absolute Neutrophil Count (ANC) ≥ 1.5×10\^9/L;

    入选标准第 9 条

    Hemoglobin (Hgb) ≥ 90 g/dl;

    入选标准第 10 条

    Platelets (Plt) ≥ 75×10\^9/L;

    入选标准第 11 条

    Bilirubin total ≤ 1.5 x ULN, or bilirubin direct < ULN for patients with bilirubin total levels >1.5 ULN;

    入选标准第 12 条

    AST/ALT ≤ 2.5 x ULN or ≤ 5.0 x ULN if liver metastases are present;

    入选标准第 13 条

    Serum creatinine < 1.5 x ULN or creatinine clearance > 50 mL/min (as calculated via Cockcroft-Gault formula based on the actual body weight of the subject ;

    入选标准第 14 条

  7. Patients must have at least one measurable lesion as defined by RECIST version 1.1 criteria.

    入选标准第 4 条

  8. Diagnosis of any other malignancy within the past 5 years (excluding carcinoma in situ, basal cell carcinoma, etc.).

    排除标准第 1 条

    Active infections such as HIV; active chronic HBV/HCV (e.g., HBV DNA ≥ 10⁴ copies/mL or ≥ 2000 IU/mL) requiring antiviral and hepatoprotective therapy before enrollment. Enrollment is allowed only when HBV DNA decreases to < 10⁴ copies/mL or < 2000 IU/mL, with continued antiviral therapy and regular monitoring of liver function and HBV DNA levels.

    排除标准第 8 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:怀孕、哺乳与避孕。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07697040,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Subjects who are able to understand and voluntarily sign informed consent forms (ICFs).
  2. Male and female subjects at the age of ≥18 and ≤75 at the time of screening.
  3. Histologically confirmed esophageal squamous cell carcinoma staged as cT2-T4a, N0-N+, M0-M1 (M1 limited to supraclavicular lymph node metastasis only).
  4. Patients must have at least one measurable lesion as defined by RECIST version 1.1 criteria.
  5. Patients who have not received any prior anti-tumor treatment for esophageal cancer.
  6. ECOG score of 0 or 1.
  7. Life expectancy ≥ 3 months.
  8. Adequate organ function (no blood transfusion and no use of granulocyte colony-stimulating factor, or other hematopoietic stimulator support within 2 weeks before the first administration of the study drug) confirmed as evidenced by:
  9. Absolute Neutrophil Count (ANC) ≥ 1.5×10\^9/L;
  10. Hemoglobin (Hgb) ≥ 90 g/dl;
  11. Platelets (Plt) ≥ 75×10\^9/L;
  12. Bilirubin total ≤ 1.5 x ULN, or bilirubin direct < ULN for patients with bilirubin total levels >1.5 ULN;
  13. AST/ALT ≤ 2.5 x ULN or ≤ 5.0 x ULN if liver metastases are present;
  14. Serum creatinine < 1.5 x ULN or creatinine clearance > 50 mL/min (as calculated via Cockcroft-Gault formula based on the actual body weight of the subject ;
  15. Female subjects must not be pregnant or breastfeeding. Female or male subjects of childbearing potential must agree to practice effective contraceptive measures throughout the study period and for 6 months after completion of study treatment.

排除标准:Exclusion Criteria:

  1. Diagnosis of any other malignancy within the past 5 years (excluding carcinoma in situ, basal cell carcinoma, etc.).
  2. Anyone allergic to any drug or any of its components in this regimen.
  3. Patients with a prior history of surgery for esophageal squamous cell carcinoma.
  4. Patients with a prior history of fistula caused by primary tumor infiltration.
  5. Patients at high risk of gastrointestinal bleeding, esophageal fistula, or esophageal perforation.
  6. Subjects with poor nutritional status, defined as BMI < 18.5 kg/m² or PG-SGA score ≥ 9.
  7. Patients with a diagnosis of pulmonary fibrosis or interstitial pneumonia within 28 days prior to enrollment.
  8. Active infections such as HIV; active chronic HBV/HCV (e.g., HBV DNA ≥ 10⁴ copies/mL or ≥ 2000 IU/mL) requiring antiviral and hepatoprotective therapy before enrollment. Enrollment is allowed only when HBV DNA decreases to < 10⁴ copies/mL or < 2000 IU/mL, with continued antiviral therapy and regular monitoring of liver function and HBV DNA levels.
  9. Presence of major cardiovascular disease, including any of the following conditions:
  10. Congestive heart failure (defined as New York Heart Association [NYHA] Class III or IV), myocardial infarction, unstable angina, coronary angioplasty, stent implantation, coronary artery bypass grafting, cerebrovascular accident (CVA), or hypertensive crisis within 6 months prior to enrollment.
  11. History of clinically significant ventricular arrhythmias (e.g., sustained ventricular tachycardia, ventricular fibrillation, torsade de pointes).
  12. Fridericia-corrected QT interval (QTcF) > 450 msec in males or > 470 msec in females.
  13. History or family history of congenital long QT syndrome.
  14. Arrhythmias requiring antiarrhythmic therapy (subjects with atrial fibrillation that has been controlled for more than 30 days prior to randomization may be enrolled).
  15. History of deep vein thrombosis, pulmonary embolism, or any other serious thromboembolic event within 3 months prior to enrollment (thrombosis related to an implanted venous access port or catheter, or superficial venous thrombosis, is not considered "serious" thromboembolism).
  16. Severe chronic diarrhea.
  17. Severe psychiatric disorder.
  18. Use of strong inhibitors or inducers of CYP3A4, CYP2C8, and UGT1A1.
  19. Participation in another clinical trial within 4 weeks prior to enrollment.
  20. Patients who, in the opinion of the investigator, are unsuitable for participation in this study.

引自 ClinicalTrials.gov, NCT07697040, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07697040,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07697040